Abstract
Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase that regulates centriole duplication. PLK4 deregulation causes centrosome number abnormalities, mitotic defects, chromosomal instability and, consequently, tumorigenesis. Therefore, PLK4 has emerged as a therapeutic target for the treatment of multiple cancers. In this review, we summarize the critical role of centrosome amplification and PLK4 in cancer. We also highlight recent advances in the development of PLK4 inhibitors and discuss potential combination therapies for cancer.
Funding Information
  • National Natural Science Foundation of China (81270598, 81473486, 81770210)
  • Key Research and Development Program of Shandong Province (2018CXGC1213)
  • Doctoral Foundation of Shandong Province (2017GSF18189)

This publication has 72 references indexed in Scilit: